We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Chinook Therapeutics Inc | NASDAQ:KDNY | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 40.39 | 40.39 | 38.38 | 0 | 01:00:00 |
From May 2023 to May 2024
10:10 AM ET -- Novartis is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Novartis agreed to acquire clinical-stage biopharmaceutical company Chinook Therapeutics for up to $3.5 billion, in a deal that will expand its portfolio of kidney disease treatments. Holders of Chinook common stock receiving $3.2 billion in cash, plus a contingent value right of up to $300 million. The deal will hand Novartis exposure to Chinook's pipeline for kidney disease treatments. Novartis expects to close the transaction in the second half of the year, subject to customary closing conditions. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
June 12, 2023 10:25 ET (14:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Chinook Therapeutics Chart |
1 Month Chinook Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
